InnoSIGN Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
18
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$22.2M
- Investors
-
6
InnoSIGN General Information
Description
Developer of mRNA-based pathway activity profiling technology designed to revolutionize precision medicine by obtaining more insight into the mechanisms of disease. The company offers to utilize extensive database with pathway activity profiles to support diagnostics and drug development, providing researchers with qPCR tests for decentralized use via a service testing facility.
Contact Information
Website
www.innosignbio.comCorporate Office
- High Tech Campus 11
- 5656 AE Eindhoven
- Netherlands
Corporate Office
- High Tech Campus 11
- 5656 AE Eindhoven
- Netherlands
InnoSIGN Timeline
InnoSIGN Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 26-Jul-2022 | $22.2M | Completed | Generating Revenue | ||
| 1. Spin-Off | 22-Mar-2022 | Completed | Startup |
InnoSIGN Comparisons
Industry
Financing
Details
InnoSIGN Competitors (3)
One of InnoSIGN’s 3 competitors is RiboPro, a Venture Capital-Backed company based in Oss, Netherlands.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| RiboPro | Venture Capital-Backed | Oss, Netherlands | ||||
| Illumina | Formerly VC-backed | San Diego, CA | ||||
| Qiagen | Formerly VC-backed | Hilden, Germany |
InnoSIGN Patents
InnoSIGN Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026017877-A1 | Method for determining hippo pathway activity | Pending | 19-Jul-2024 | ||
| EP-4569139-A1 | Prediction and monitoring of immunotherapy in cancer | Inactive | 12-Aug-2022 | ||
| US-20260062755-A1 | Prediction and monitoring of immunotherapy in cancer | Pending | 12-Aug-2022 | ||
| WO-2024033063-A1 | Prediction and monitoring of immunotherapy in cancer | Inactive | 12-Aug-2022 | ||
| EP-4434034-A1 | Assessment of gr cellular signaling pathway activity using mathematical modelling of target gene expression | Inactive | 15-Nov-2021 | G16B5/00 |
InnoSIGN Signals
InnoSIGN Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Brabantse Ontwikkelings Maatschappij | Venture Capital | Minority | ||
| Casdin Capital | Venture Capital | Minority | ||
| Life Science Angels | Angel Group | Minority | ||
| NuFund Venture Group | Angel Group | Minority | ||
| Rivermount VC Fund | Venture Capital | Minority |
InnoSIGN FAQs
-
When was InnoSIGN founded?
InnoSIGN was founded in 2022.
-
Where is InnoSIGN headquartered?
InnoSIGN is headquartered in Eindhoven, Netherlands.
-
What is the size of InnoSIGN?
InnoSIGN has 18 total employees.
-
What industry is InnoSIGN in?
InnoSIGN’s primary industry is Biotechnology.
-
Is InnoSIGN a private or public company?
InnoSIGN is a Private company.
-
What is InnoSIGN’s current revenue?
The current revenue for InnoSIGN is .
-
How much funding has InnoSIGN raised over time?
InnoSIGN has raised $22.2M.
-
Who are InnoSIGN’s investors?
Brabantse Ontwikkelings Maatschappij, Casdin Capital, Life Science Angels, NuFund Venture Group, and Rivermount VC Fund are 5 of 6 investors who have invested in InnoSIGN.
-
Who are InnoSIGN’s competitors?
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process